SCLY and metabolic dysfunction-associated steatotic liver disease: The downregulation of SCLY suggests a change in Se sources for selenoprotein synthesis occurs in NAFLD livers, further implicating SCLY as a potential target or localized biomarker for obesity-induced cancers, particularly in the liver [17].